{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T11:13:31Z","timestamp":1759058011028},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,5,6]],"date-time":"2015-05-06T00:00:00Z","timestamp":1430870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s13760-015-0479-z","type":"journal-article","created":{"date-parts":[[2015,5,5]],"date-time":"2015-05-05T10:14:17Z","timestamp":1430820857000},"page":"635-642","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Longitudinally extensive transverse myelitis in neuromyelitis optica: a prospective study of 13 Caucasian patients and literature review"],"prefix":"10.1007","volume":"115","author":[{"given":"Rodica","family":"B\u0103la\u015fa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smaranda","family":"Maier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Bajko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Motataianu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Cri\u015fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"B\u0103la\u015fa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,6]]},"reference":[{"key":"479_CR1","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106\u20132112","journal-title":"Lancet"},{"key":"479_CR2","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485\u20131489","journal-title":"Neurology"},{"key":"479_CR3","doi-asserted-by":"crossref","unstructured":"Roemer SF, Luchinetti C (2010) Immune effector heterogeneity in multiple sclerosis and related CNS inflammatory demyelinating disorders. In: Kilpatrick T, Ransohoff RM, Wesselingh S (ed) Inflammatory diseases of the central nervous system. Cambridge University Press, pp 47\u201373","DOI":"10.1017\/CBO9781139195805.006"},{"key":"479_CR4","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11910-008-0066-2","volume":"8","author":"B Cree","year":"2008","unstructured":"Cree B (2008) Neuromyelitis optica: diagnosis, pathogenesis and treatment. Curr Neurol Neurosci Rep 8:427\u2013433","journal-title":"Curr Neurol Neurosci Rep"},{"key":"479_CR5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1212\/01.WNL.0000154673.37555.6F","volume":"64","author":"B Weinshenker","year":"2005","unstructured":"Weinshenker B, Vukusic S, Wingerchuk D et al (2005) NMO-IgG predicts relapse in patients with longitudinally extensive \u201cidiopathic\u201d transverse myelitis. Neurology 64:621\u2013630","journal-title":"Neurology"},{"key":"479_CR6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/jnnp.60.4.382","volume":"60","author":"JI O\u2019Riordan","year":"1996","unstructured":"O\u2019Riordan JI, Gallagher HL, Thompson AJ et al (1996) Clinical CSF, and MRI findings in Devic\u2019s neuromyelitis optica. J Neurol Neurosurg Psychiatry 60:382\u2013387","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"479_CR7","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444\u20131452","journal-title":"Neurology"},{"key":"479_CR8","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","volume":"51","author":"RN Mandler","year":"1998","unstructured":"Mandler RN, Ahmed W, Dencoff JE (1998) Devic\u2019s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51:1219\u20131220","journal-title":"Neurology"},{"key":"479_CR9","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805\u2013815","journal-title":"Lancet Neurol"},{"key":"479_CR10","doi-asserted-by":"crossref","unstructured":"Matiello M, Weinshenker BG (2010) Neuromyelitis optica. In: Lucchinetti CF, Hohlfeld R (ed) Multiple sclerosis. Saunders Elsevier, pp 258\u2013275","DOI":"10.1016\/B978-1-4160-6068-0.00013-9"},{"key":"479_CR11","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135:1834\u20131849","journal-title":"Brain"},{"key":"479_CR12","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2013.3890","volume":"70","author":"J Kitley","year":"2013","unstructured":"Kitley J, Leite MI, Kuker W et al (2013) Longitudinally extensive transverse myelitis with and without aquaporin-4 antibodies. JAMA Neurol 70:1375\u20131381","journal-title":"JAMA Neurol"},{"key":"479_CR13","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473\u2013477","journal-title":"J Exp Med"},{"key":"479_CR14","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1212\/01.wnl.0000345066.57745.50","volume":"72","author":"EC Klawiter","year":"2009","unstructured":"Klawiter EC, Alvarez E, Xu J et al (2009) NMO-IgG detected in CSF in seronegative neuomyelitis optica. Neurology 72:1101\u20131103","journal-title":"Neurology"},{"key":"479_CR15","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","volume":"130","author":"T Takahashi","year":"2007","unstructured":"Takahashi T, Fujiara K, Nakashima I et al (2007) Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130:1235\u20131243","journal-title":"Brain"},{"key":"479_CR16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","volume":"306","author":"S Jarius","year":"2011","unstructured":"Jarius S, Paul F, Franciotta et al (2011) Cerebrospinal fluid findings in aquaporin-4 antibody-positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 306:82\u201390","journal-title":"J Neurol Sci"},{"key":"479_CR17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","volume":"71","author":"J Kitley","year":"2014","unstructured":"Kitley J, Waters P, Woodhall M et al (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies. A comparative study. JAMA Neurol 71:276\u2013283","journal-title":"JAMA Neurol"},{"issue":"1","key":"479_CR18","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1212\/NXI.0000000000000062","volume":"2","author":"SS Zamvil","year":"2015","unstructured":"Zamvil SS, Slavin AJ (2015) Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2(1):e62. doi: 10.1212\/NXI.0000000000000062 (eCollection 2015 Feb. Review)","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"479_CR19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458511431077","volume":"18","author":"DM Wingerchuk","year":"2012","unstructured":"Wingerchuk DM, Weinshenker B (2012) The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler J 18:5\u201310","journal-title":"Mult Scler J"},{"key":"479_CR20","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","volume":"130","author":"H Merle","year":"2012","unstructured":"Merle H, Olindo S, Jeannin S et al (2012) Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 130:858","journal-title":"Arch Ophthalmol"},{"key":"479_CR21","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","volume":"13","author":"S Watanabe","year":"2007","unstructured":"Watanabe S, Misu T, Miyazama I et al (2007) Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 13:968\u2013974","journal-title":"Mult Scler"},{"key":"479_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","volume":"261","author":"C Trebst","year":"2014","unstructured":"Trebst C, Jarius S, Berthele A et al (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS). J Neurol 261:1\u201316","journal-title":"J Neurol"},{"issue":"3","key":"479_CR23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1212\/NXI.0000000000000038","volume":"1","author":"K Fujihara","year":"2014","unstructured":"Fujihara K, Nakashima I (2014) Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy? Neurol Neuroimmunol Neuroinflamm 1(3):38. doi: 10.1212\/NXI.0000000000000038","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-015-0479-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13760-015-0479-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-015-0479-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T16:56:37Z","timestamp":1559494597000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13760-015-0479-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,6]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["479"],"URL":"https:\/\/doi.org\/10.1007\/s13760-015-0479-z","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,6]]}}}